Hemolytic Anemia in Inflammatory Bowel Disease: Our “Gut” Tells Us to Blame the Drug

Abstract

Abstract Background Several studies determined that autoimmune hemolytic anemia (AIHA) is a rare extraintestinal IBD manifestation, related to the underlying disease activity. However, evidence linking biologic therapy to AIHA is sparse. Methods This article reviews the evidence on the association of these clinical phenomena. Results There are two retrospective studies and a few case reports linking biologic therapies to AIHA. Conclusions While some autoimmune phenomenon triggered by our biologic therapies have been well recognized, we do not find the evidence associating these therapies to AIHA sufficiently compelling.